The majority of analysts have given Harmony Biosciences a bullish rating, indicating positive sentiment. The average price target has increased slightly, suggesting potential for stock price appreciation. The company's strong revenue growth and net margin are positive indicators, although the lower ROE may be a concern for some investors.